KS Biomedix Secures European Deal Over TransMID™-R

By Business Review Editor

Pharma Deals Review: Vol 2002 Issue 29 (Table of Contents)

Published: 2 Oct-2002

DOI: 10.3833/pdr.v2002.i29.990     ISSN: 1756-7874

Section: Licensing



KS Biomedix entered into a licensing agreement with Nycomed for its TransMID™-R for the treatment of high grade glioma with a value up to US$60 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details